Date: 2021/6/10
Your Name: Shih-Hang Tai
Manuscript Title: Cinnamophilin enhances temozolomide-induced cytotoxicity against malignant glioma: th
roles of ROS and cell cycle arrest

Manuscript number (if known): TCR-20-3426-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	✓None	All the financial support was provided by the ministry of science and technology in Taiwan.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past <u>✓</u> None	36 months
3	Royalties or licenses	✓None	
4	Consulting fees	<u>√</u> None	

5	Payment or honoraria for	<u>√</u> None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	<u>√</u> None		
	testimony			
7	Support for attending meetings and/or travel	<u>✓</u> None		
8	Patents planned, issued or	<u>√</u> None		
	pending			
9	Participation on a Data	<u>✓</u> None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	<u>✓</u> None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	<u>✓</u> None		
12	Descint of aguinment	✓None		
12	Receipt of equipment, materials, drugs, medical	<u>v</u> None		
	writing, gifts or other			
	services			
13	Other financial or non-	√None		
	financial interests	_		
Ple	Please summarize the above conflict of interest in the following box:			

All the financial support was provided by the ministry of science and technology in Taiwan.		

Date: 2021/6/10
Your Name: Yu-Wen Lin
Manuscript Title: Cinnamophilin enhances temozolomide-induced cytotoxicity against malignant glioma: the
roles of ROS and cell cycle arrest

Manuscript number (if known): TCR-20-3426-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	✓None	All the financial support was provided by the ministry of science and technology in Taiwan.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past <u>✓</u> None	36 months
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>√</u> None	

5	Payment or honoraria for	<u>√</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
_		(*)	
7	Support for attending meetings and/or travel	<u>√</u> None	
	g ,		
8	Patents planned, issued or	<u>√</u> None	
	pending		
9	Participation on a Data	<u>√</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>√</u> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>√</u> None	
		7.1	
12	Receipt of equipment,	<u>√</u> None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√None	
13	financial interests	<u>· INOTIE</u>	
	inialiciai inici ests		
Dla	ease summarize the above o	onflict of interest in the	a following hox:

All the financial support was provided by the ministry of science and technology in Taiwan.	

Date: <u>2021/6/10</u>	
Your Name: <u>Tung-Yi Huang</u>	
Manuscript Title: Cinnamophilin enhances temozolo	mide-induced cytotoxicity against malignant glioma: th
roles of ROS and cell cycle arrest	
Manuscript number (if known): TCR-20-3426-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	✓None	All the financial support was provided by the ministry of science and technology in Taiwan.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past <u>✓</u> None	36 months
3	Royalties or licenses	✓None	
4	Consulting fees	<u>√</u> None	

5	Payment or honoraria for	<u>√</u> None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	<u>√</u> None		
	testimony			
7	Support for attending meetings and/or travel	<u>✓</u> None		
8	Patents planned, issued or	<u>√</u> None		
	pending			
9	Participation on a Data	<u>✓</u> None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	<u>✓</u> None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	<u>✓</u> None		
12	Descint of aguinment	✓None		
12	Receipt of equipment, materials, drugs, medical	<u>v</u> None		
	writing, gifts or other			
	services			
13	Other financial or non-	√None		
	financial interests	_		
Ple	Please summarize the above conflict of interest in the following box:			

All the financial support was provided by the ministry of science and technology in Taiwan.		

Date: <u>2021/6/10</u>	
Your Name: Che-Chao Chang	
Manuscript Title: Cinnamophilin enhances temozolomide-induced cytotoxicity against m	alignant glioma: th
roles of ROS and cell cycle arrest	
Manuscript number (if known): TCR-20-3426-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>✓</u> None	All the financial support was provided by the ministry of science and technology in Taiwan.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past <u>✓</u> None	36 months
3	Royalties or licenses	✓None	
4	Consulting fees	✓None	

5	Payment or honoraria for	<u>√</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
_		(*)	
7	Support for attending meetings and/or travel	<u>√</u> None	
	g ,		
8	Patents planned, issued or	<u>√</u> None	
	pending		
9	Participation on a Data	<u>√</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>√</u> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>√</u> None	
		7.1	
12	Receipt of equipment,	<u>√</u> None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√None	
13	financial interests	<u>· INOTIE</u>	
	inialiciai inici ests		
Dla	ease summarize the above o	onflict of interest in the	a following hox:

All the financial support was provided by the ministry of science and technology in Taiwan.	

Date: 2021/6/10	
Your Name: <u>Liang-Chun Chao</u>	
Manuscript Title: Cinnamophilin enhances temozolo	mide-induced cytotoxicity against malignant glioma: th
roles of ROS and cell cycle arrest	
Manuscript number (if known): TCR-20-3426-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	✓None	All the financial support was provided by the ministry of science and technology in Taiwan.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past <u>✓</u> None	36 months
3	Royalties or licenses	✓None	
4	Consulting fees	<u>√</u> None	

5	Payment or honoraria for	<u>√</u> None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	<u>√</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>✓</u> None
8	Patents planned, issued or	<u>√</u> None
	pending	
9	Participation on a Data	<u>✓</u> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	<u>✓</u> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	<u>✓</u> None
12	Descint of aguinment	✓None
12	Receipt of equipment, materials, drugs, medical	<u>v</u> None
	writing, gifts or other	
	services	
13	Other financial or non-	√None
	financial interests	_
Ple	ease summarize the above o	onflict of interest in the following hox:

All the financial support was provided by the ministry of science and technology in Taiwan.			

Date: 2021/6/10	
Your Name: <u>Tian-Shung Wu</u>	
Manuscript Title: Cinnamophilin enhances temozolo	mide-induced cytotoxicity against malignant glioma: th
roles of ROS and cell cycle arrest	
Manuscript number (if known): TCR-20-3426-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	✓None	All the financial support was provided by the ministry of science and technology in Taiwan.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	✓None	
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	<u>√</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
_		(*)	
7	Support for attending meetings and/or travel	<u>√</u> None	
	g ,		
8	Patents planned, issued or	<u>√</u> None	
	pending		
9	Participation on a Data	<u>√</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>√</u> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>√</u> None	
		7.1	
12	Receipt of equipment,	<u>√</u> None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√None	
13	financial interests	<u>· INOTIE</u>	
	inialiciai inici ests		
Dla	ease summarize the above o	onflict of interest in the	a following hox:

All the financial support was provided by the ministry of science and technology in Taiwan.	

Date: <u>2021/6/10</u>
our Name: E-Jian Lee
Manuscript Title: Cinnamophilin enhances temozolomide-induced cytotoxicity against malignant glioma: tl
roles of ROS and cell cycle arrest
Manuscript number (if known): TCR-20-3426-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	✓None	All the financial support was provided by the ministry of science and technology in Taiwan.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past <u>✓</u> None	36 months
3	Royalties or licenses	✓None	
4	Consulting fees	<u>√</u> None	

5	Payment or honoraria for	<u>√</u> None				
	lectures, presentations,					
	speakers bureaus,					
	manuscript writing or					
	educational events					
6	Payment for expert	<u>√</u> None				
	testimony					
7	Support for attending meetings and/or travel	<u>√</u> None				
	meetings and/or traver					
8	Patents planned, issued or	<u>√</u> None				
	pending					
9	Participation on a Data	<u>√</u> None				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role in other board, society,	<u>√</u> None				
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	<u>√</u> None				
12	Receipt of equipment,	<u>√</u> None				
	materials, drugs, medical					
	writing, gifts or other					
42	services	Alama				
13	Other financial or non-	<u>√</u> None				
	financial interests					
Ple	ease summarize the above o	conflict of interest in the following box:				

All the financial support was provided by the ministry of science and technology in Taiwan.				